Australia markets closed

Oxford Biomedica plc (OXBDF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
2.43000.0000 (0.00%)
At close: 09:39AM EDT
Full screen
Loading interactive chart…
  • GlobeNewswire

    Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results

    Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results Three-year revenue CAGR increased to more than 35%, up from prior guidance of more than 30%Projected FY2024 revenue range of £126 million to £134 million, reflecting the successful integration of ABL Europe and anticipated growth from new and existing client programmesFY2023 revenues and EBITDA expected to be in line with guidance provided at the Interim ResultsFY2023 Preliminary Results to be reported on

  • GlobeNewswire

    Oxford Biomedica completes acquisition of ABL Europe

    Oxford Biomedica completes acquisition of ABL Europe Strengthens Oxford Biomedica’s position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple sites in EU, US and UKExpands Oxford Biomedica’s ability to serve more clients, unlocking development capacity and increasing revenues3.2 per cent of the Company’s share capital issued to Institut Mérieux at a share price of 407.4p Oxford, UK – 29 January 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Bio

  • GlobeNewswire

    Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing

    Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing Oxford, UK – 23 January 2024: On Wednesday 7 February, Oxford Biomedica, a quality and innovation-led cell and gene therapy CDMO, will host a free 60-minute webinar offering an in-depth view of the customer journey from client onboarding to the successful manufacture of adeno-associated virus and lentiviral vectors.. This event will demonstrate how unique and transferable technical expertis